| Literature DB >> 32117248 |
Lokesh Sharma1, Jingjing Feng1,2, Clemente J Britto1, Charles S Dela Cruz1.
Abstract
Bacterial lung infections are major healthcare challenges killing millions of people worldwide and resulting in a huge economic burden. Both basic and clinical research have elucidated host mechanisms that contribute to the bacterial clearance where an indispensable role of immune cells has been established. However, the role of respiratory epithelial cells in bacterial clearance has garnered limited attention due to their weak inflammatory or phagocytic ability compared to immune cells such as macrophages and neutrophils. These studies often underappreciate the fact that epithelial cells are the most abundant cells in the lung, not only serving as building blocks but also providing immune protection throughout the lung. Epithelial cells function either independently to eradicate the pathogen or communicate with immune cells to orchestrate pathogen clearance. The epithelial cells have multiple mechanisms that include mucus production, antimicrobial peptide production, muco-ciliary clearance, and phagocytosis, all of which contribute to their direct antibacterial function. Secretion of cytokines to recruit immune cells and potentiate their antimicrobial activities is a pathway by which the epithelium contributes to bacterial clearance. Successful pathogens outsmart epithelial resistance and find a way to replicate in sufficient numbers to establish infections in the airway or lung epithelial surfaces. In this mini-review, we discuss evidences that establish important roles for epithelial host defense against invading respiratory bacterial pathogens and demonstrate how pathogens outsmart these epithelial immune mechanisms to successfully establish infection. Finally, we discuss briefly how to boost epithelial immunity to improve outcomes in bacterial lung infections.Entities:
Keywords: bacterial dissemination; epithelial immunity; host pathogen interaction; lung epithelium; pathogen evolution
Mesh:
Substances:
Year: 2020 PMID: 32117248 PMCID: PMC7027138 DOI: 10.3389/fimmu.2020.00091
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Pathogen mechanisms to circumvent direct killing of bacteria by lung epithelial cells. (1) Epithelial cells possess phagocytic ability. (2) Bacteria harbor structures to evade epithelial phagocytosis, such as capsular polysaccharides of Klebsiella pneumoniae. (3) Altered phenotypes in pathogens cause chronic infections e.g., small colony variant of Staphylococcus aureus. (4) Pathogens can live inside the lung epithelium e.g., Bordetella or Legionella. (5) Epithelium releases antimicrobial peptides during lung infections, which bind to the pathogen surface and neutralize the pathogen. (6) During inflammation, a large number of proteins are accumulated in the lung. AMPs interact with other proteins and lose their antimicrobial potency. (7) P. aeruginosa elastase breaks down human LL37 in a dose dependent manner. (8) Pathogen recruited neutrophils contribute to the acidity. SPLUNC loses its function in an acidic environment; also, neutrophil elastases can break down SPLUNC. AMPs, antimicrobial proteins and peptides; SPLUNC, short palate lung and nasal epithelium clone 1.
Figure 2Pathogen tactics to avoid indirect killing during lung infections. (1) Lung epithelium secrete cytokines and chemokines to recruit immune cells in the lung. (2) Klebsiella inhibits the activation of NFkB and MAPK pathway by promoting the expression of ubiquitinating enzyme CYLD in lung epithelial cells. (3) Gram positive pathogens break down host hyaluronan. (4) Streptococcus cleaves and inactivates IL-8. (5) Chlamydia targets TRAF3 in the epithelial cells. (6) Pseudomonas aeruginosa inhibits ciliary beat function. (7) Macrophages and dendritic cells carry TB from the lung to secondary lymphoid organs. (8) Pathogens induce damage to lung cells or to the extracellular matrix. IL-8, interleukin-8; NFkB, nuclear factor kappa B; MAPK, mitogen activated protein kinase; TRAF3, TNF receptor-associated factor 3.